Emotional adjustment in adults with chronic migraine treated with anti-CGRP antibodies
Studies how adults with chronic migraine cope emotionally while on anti-CGRP treatment.
Plain-language title generated from the registry record
Registry title: Psychological Support for Chronic Migraine Patients Treated With Anti-CGRP (Anti-Calcitonin Gene-Related Peptide ) Monoclonal Antibodies
Key facts
- Where
- Nancy, FranceSee the site
Where in France
- CHRUNancy, FranceNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Central Hospital, Nancy, France
- Trial code
- NCT07877493
- Record updated
- 16 October 2026
- Original description
Chronic migraine is a disabling neurological condition that can significantly affect quality of life, emotional well-being, social participation, and daily functioning. Although anti-CGRP monoclonal antibodies have substantially improved migraine management for many patients, little is known about the psychological experiences and adjustment processes associated with these treatments.Read full original descriptionShow less
Psychological Adjustment Following Extreme Therapeutic Responses to Anti-Calcitonin Gene-Related Peptide (CGRP) Treatment in Patients With Chronic Migraine: A Mixed Quantitative and Qualitative Study
Chronic migraine is a disabling neurological condition that can significantly affect quality of life, emotional well-being, social participation, and daily functioning. Although anti-CGRP monoclonal antibodies have substantially improved migraine management for many patients, little is known about the psychological experiences and adjustment processes associated with these treatments.
This observational study aims to explore the psychological adaptation of adults with chronic migraine treated with anti-CGRP monoclonal antibodies. Participants will complete standardized questionnaires assessing migraine-related disability, headache impact, anxiety and depressive symptoms, quality of life, and treatment experiences at treatment initiation and after 12 months of follow-up. Psychological interviews will also be conducted to explore patients' perceptions, coping strategies, and lived experiences of treatment.
The study seeks to identify factors associated with positive or negative psychological adaptation to treatment and to better understand patients' emotional experiences throughout their care pathway. The findings may contribute to the development of tailored psychological support interventions for individuals living with chronic migraine.
Inclusion: • Diagnosis of chronic migraine established by a neurologist; Treatment with an anti-CGRP monoclonal antibody administered at the CHRU de Nancy; Completion of the initial psychological interview; Availability of analyzable clinical and psychological data.
Exclusion: -.